FindTrial
Sign In

Vedolizumab placebo

DRUG6 trials

Sponsors

Takeda, Genentech, Inc., Millennium Pharmaceuticals, Inc.

Conditions

Colitis, UlcerativeCrohn's DiseaseHematopoietic Stem CellsPouchitisUlcerative Colitis

Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
CompletedNCT03558152
Genentech, Inc.Ulcerative Colitis
Start: 2018-10-26End: 2021-12-15Updated: 2023-04-14

Phase 3

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
CompletedNCT02039505
TakedaUlcerative Colitis
Start: 2014-02-04End: 2018-06-28Updated: 2019-04-25
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
CompletedNCT02038920
TakedaCrohn's Disease
Start: 2014-01-28End: 2019-05-21Updated: 2019-12-09
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
CompletedNCT02497469
TakedaColitis, Ulcerative
Start: 2015-06-29End: 2019-01-18Updated: 2020-01-28
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
CompletedNCT03657160
Millennium Pharmaceuticals, Inc.Hematopoietic Stem Cells
Start: 2019-02-06End: 2022-05-09Updated: 2023-06-06

Phase 4

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
CompletedNCT02790138
TakedaPouchitis
Start: 2016-10-12End: 2021-02-02Updated: 2022-02-24

Related Papers

Patients with ulcerative colitis that have endoscopic Mayo score 1 and active histologic inflammation have similar outcomes to mild-moderate patients with Mayo score 2: a post hoc analysis of the VARSITY trial.
2025-11-26
Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.
2025-03-121 citations
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis.
2024-12-162 citations
Practical considerations of promising zone design for interim sample size Re-estimation: An application to GRAPHITE for graft vs host disease.
2024-11-261 citations
Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial.
2024-07-166 citations
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
2024-06-0622 citations
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Blood Advances2023-09-1223 citations
Vedolizumab for the Treatment of Chronic Pouchitis
New England Journal of Medicine2023-03-29101 citations
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis
Clinical Gastroenterology and Hepatology2022-08-0435 citations
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis
Scandinavian Journal of Gastroenterology2022-07-302 citations
OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial
Journal of Crohn s and Colitis2022-01-0110 citations
P547 Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
Journal of Crohn s and Colitis2022-01-012 citations
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
Inflammatory Bowel Diseases2021-12-3014 citations
S768 Costs for Treating Patients With Ulcerative Colitis With Vedolizumab or Adalimumab Based on Endoscopic Improvement Data From the VARSITY Trial
The American Journal of Gastroenterology2021-10-01
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
Journal of Gastroenterology and Hepatology2021-08-1913 citations
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)
Gastroenterology2021-06-1545 citations
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.
2021-06-0913 citations
Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial
Digestion2021-01-0112 citations
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
Intestinal Research2020-07-0824 citations
DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial
Journal of Crohn s and Colitis2020-01-012 citations

10 more papers not shown